Eris Lifesciences · NSE: ERIS · BSE: 540596
Q1 FY22 results · Apr–Jun 2021
Eris Lifesciences reported revenue from operations of ₹349.27 crore (up 19.1% from Q1 FY21) and net profit of ₹106.66 crore (up 19.8% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 349.27 | 293.24 | +19.1% | 278.21 | +25.5% |
| Other income | 5.87 | 1.34 | +338.0% | 2.21 | +165.0% |
| Total income | 355.13 | 294.58 | +20.6% | 280.42 | +26.6% |
| Profit before tax | 117.10 | 94.64 | +23.7% | 84.73 | +38.2% |
| Net profit for the period | 106.66 | 89.02 | +19.8% | 68.25 | +56.3% |
| EPS, basic (₹) | 7.86 | 6.56 | +19.8% | 5.03 | +56.3% |
| Net margin (%) | 30.5 | 30.4 | 24.5 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 306.30 | 261.48 | +17.1% | 256.85 | +19.3% |
| Other income | 6.45 | 1.41 | +357.2% | 2.75 | +134.6% |
| Total income | 312.74 | 262.89 | +19.0% | 259.60 | +20.5% |
| Profit before tax | 117.30 | 92.16 | +27.3% | 86.43 | +35.7% |
| Net profit for the period | 106.72 | 87.13 | +22.5% | 69.35 | +53.9% |
| EPS, basic (₹) | 7.86 | 6.42 | +22.4% | 5.11 | +53.8% |
| Net margin (%) | 34.8 | 33.3 | 27.0 |
Consolidated
- Filed with BSE
- 29 Jul 2021, 19:52 IST
- Board meeting
- 29 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jul 2021, 19:52 IST
- Board meeting
- 29 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE